Ragweed Pollen Allergy Treatment Market

Ragweed Pollen Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030

Ragweeds are flowering plants of the genus Ambrosia in the aster family, Asteraceae. The pollen from ragweed causes allergy symptoms in numerous people. Ragweed pollen season generally hits the Midwest U.S. in early to mid-August and lasts until the end of September or when temperatures significantly decrease.
Ragweed allergy occurs when the immune system has an inappropriate response to ragweed pollen. Normally, the immune system promotes chemical changes in the body that help fight off harmful invaders, such as viruses and bacteria. In people with ragweed allergies, however, the immune system mistakenly identifies the harmless pollen as a dangerous intruder and begins to fight against it.
A single ragweed plant can produce 1 billion grains of pollen per season, which is carried by the wind traveling hundreds of miles away. Itchy, watery eyes, stuffy, runny nose, sneering, headache, and scratchy throat are common symptoms of ragweed allergy.
According to several research studies that compared the length of ragweed seasons from 1995 to 2015, those who suffer from pollen allergies are indeed suffering longer each year, and there seems to be no sign of it slowing down. Moreover, it is becoming worse each year, especially in countries in North America.

Numerous pooled research studies indicated that climate change across the globe is more prone to ragweed pollen allergy and affects a large population. Moreover, new product development, such as Xolair from the house of Genentech to treat allergic conditions, is likely to drive the market.
However, a lack of awareness among patients about allergy immunotherapy is estimated to restrain the market

In terms of region, the global ragweed pollen allergy treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is projected to dominate the global market during the forecast period.
North America is anticipated to account for a significant share of the global market due to high prevalence of ragweed allergies
According to the Asthma and Allergy Foundation of America, every year, around 23 million people in the U.S. have symptoms from ragweed pollen allergy
Europe is expected to account for a substantial share of the market, in terms of revenue, during the forecast period due to an increase in patient population and a rise in adoption of treatment
In Europe, ragweed is most commonly reported in areas of northern Italy and southern France and According to Nature Climate Change, ragweed is likely to be found in Germany, U.K., and Northern Europe in the next few years.